Clinical trials: Colorectal Diseases
Metastatic Colorectal Cancer
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).
This is a Phase IV, single-arm, prospective, open-label, multicenter, interventional study to evaluate safety and efficacy of regorafenib in patients with mCRC who have been previously treated with fluoropyrimidine …
- Trial name
- NCT03564938
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 13 sites in India
- Volunteers
- 100 people
- Sponsor
- Bayer
Rectal Cancer, Chemotherapy Effect
Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Preoperative radiation with single agent chemotherapy as sensitizer is the standard care of locally advanced rectal cancer. Local irradiation significantly increases surgical complications and impairs quality of life.
- Trial name
- NCT03975049
- Testing
- Chemoradiation, FOLFOXIRI Protocol, Folfox Protocol
- Volunteers
- 933 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer, Surgery--Complications
Effect of the Nutraceutical "MICODIGEST 2.0" on the Complications After Surgery for Colorectal Cancer
Most of Colorectal cancer (CRC) diagnosed are candidates for surgical resection with curative intent, although colorectal surgery is associated with some complications that could be life-threatening.
- Trial name
- NCT04821258
- Testing
- MICODIGEST 2.0 supplement
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Fundacin Biomedica Galicia Sur
Rectal Cancer
The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer
Rationale and background: Predictive factors are needed to discriminate chemoradiotherapy responders from non-responders and to individualize the treatment regime.
- Trial name
- CYTORECT (NCT02077296)
- Where
- Netherlands
- Volunteers
- 34 people
- Sponsor
- St. Antonius Hospital
Rectal Neoplasms
Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer
The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the…
- Trial name
- COMREC (NCT05871762)
- Testing
- Registry study, no specific intervention
- Where
- China
- Volunteers
- 3,705 people
- Sponsor
- Peking Union Medical College Hospital
Neoplasm Metastasis, Colorectal Cancer
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
The FIRE-3 trial is a multicenter randomized phase III trial investigating 5-FU, folinic acid and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line treatment of metastatic colorectal cancer.
- Trial name
- NCT00433927
- Testing
- 5-FU, folinic acid, irinotecan
- Where
- Germany
- Volunteers
- 568 people
- Sponsor
- PD Dr. med. Volker Heinemann
Colon Cancer, Liver Metastasis Colon Cancer
Hepatopulmonary Radio-sterilization With Immunotherapy
In this protocol the investigators aim to overcome hepatic-pulmonary metastases-induced resistance to immunotherapy through high dose radiation therapy (SBRT) targeted to the metastases themselves, aiming, when possible, to…
- Conditions
- Colon Cancer, Liver Metastasis Colon Cancer, Rectal Cancer
- Trial name
- TROS-8 (NCT06053996)
- Testing
- Hepatopulmonary radio-sterilization
- Where
- Israel
- Volunteers
- 44 people
- Sponsor
- Sheba Medical Center
Colorectal Cancer, Dermatologic Complications
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
RATIONALE: Questionnaires that patients can use to assess skin toxicities related to treatment may help identify the intermediate-and long-term effects of cetuximab, panitumumab, or erlotinib hydrochloride.
- Conditions
- Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
- Trial name
- NCT01416688
- Testing
- assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
- Where
- 113 sites in United States
- Volunteers
- 146 people
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer
A Study in Second Line Metastatic Colorectal Cancer
The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.
- Trial name
- NCT01183780
- Testing
- Ramucirumab, Irinotecan, Folinic Acid
- Where
- 213 sites in United States, Argentina and 24 more
- Volunteers
- 1,072 people
- Sponsor
- Eli Lilly and Company
Rectal Cancer
Timisnar - Biomarkers Substudy (Timisnar-mirna)
Neoadjuvant chemoradiotherapy (nCHT) followed by surgery is the mainstay treatment for locally advanced rectal cancer, leading to significant decrease in tumor size (downsizing) and a shift towards earlier disease stage in the…
- Trial name
- TiMiSNAR-miRNA (NCT03962088)
- Testing
- miRNA
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Colon Polyp, Colon Adenoma
Impact of Screen Size on Colorectal Adenoma Detection
The purpose of this study is to assess whether the use of large screen during colonoscopy will increase adenoma detection rate.
- Conditions
- Colon Polyp, Colon Adenoma, Colorectal Neoplasms
- Trial name
- NCT04749303
- Testing
- Large Screen
- Where
- Hong Kong
- Volunteers
- 656 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Metastatic Colorectal Cancer, Radiotherapy
Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer
This study is a randomized phase II trial of maintenance chemotherapy versus consolidative radiotherapy plus maintenance chemotherapy for patients with unresectable metastatic colorectal cancer (MCRC).
- Trial name
- MCRC-LC1 (NCT03142282)
- Testing
- maintenance chemotherapy, Consolidative Radiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CRC (Colorectal Cancer)
Monocentric Retrospective and Prospective Observational Study of Patients With Colorectal Cancer
Monocentric retrospective and prospective observational study of patients with colorectal cancer
- Trial name
- CRC-R (NCT07663162)
- Volunteers
- 2,000 people
- Sponsor
- IRCCS San Raffaele
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
HER2-positive Solid Tumors, HER2-positive Breast Cancer
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies
- Conditions
- HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer
- Trial name
- NCT04278144
- Testing
- BDC-1001, Nivolumab
- Where
- 21 sites in United States, France and 2 more
- Volunteers
- 175 people
- Sponsor
- Bolt Biotherapeutics, Inc.
Rectal Cancer, Adaptive Radiotherapy
the Efficacy of MR-guided Online Adaptive Radiotherapy for Locally Advanced Rectal Cancer
Based on preliminary findings on the motion error of the clinical target volume (CTV) in MR-guided adaptive radiotherapy (MRgART) for locally advanced rectal cancer (LARC), this study aims to reduce CTV-to-PTV margins and…
- Trial name
- NCT07080411
- Testing
- short course radiotherapy using MR-linac
- Volunteers
- 49 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer, Head and Neck Cancer
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
- Conditions
- Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer
- Trial name
- DELFI-L101 (NCT04825834)
- Testing
- Blood Sample Collection
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 2,992 people
- Sponsor
- Delfi Diagnostics Inc.
Colorectal Cancer
Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- PIMABI (NCT00655499)
- Testing
- Panitumumab, Irinotecan hydrochloride, Chromogenic in situ hybridization
- Where
- 9 sites in France
- Volunteers
- 65 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Neoplasms, Incisional Hernia
AP-NOSES: A Prospective Multicentre Registry of Natural Orifice Specimen Extraction in Minimally Invasive Colorectal Surgery
Natural orifice specimen extraction (NOSE) is a minimally invasive colorectal surgical technique in which the surgical specimen is removed through a natural orifice, including transanal or transvaginal routes, thereby avoiding an…
- Trial name
- AP-NOSES (NCT07615036)
- Testing
- Natural Orifice Specimen Extraction, Transabdominal Specimen Extraction
- Where
- Singapore
- Volunteers
- 800 people
- Sponsor
- Singapore General Hospital
Colorectal Cancer
Chemoradiation and Endothelial Progenitor Cells in Colorectal Cancer
Colorectal cancer (CRC) is one of the common malignancies worldwide, accounting for a significant percentage of cancer mortality.
- Trial name
- NCT00325871
- Testing
- concurrent chemoradiation
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Mackay Memorial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.